Xtant Medical Holdings, Inc. (XTNT): Price and Financial Metrics
GET POWR RATINGS... FREE!
XTNT Stock Summary
- XTNT has a market capitalization of $58,500,180 -- more than approximately only 10.23% of US stocks.
- Price to trailing twelve month operating cash flow for XTNT is currently 133.26, higher than 96.74% of US stocks with positive operating cash flow.
- In terms of twelve month growth in earnings before interest and taxes, Xtant Medical Holdings Inc is reporting a growth rate of 413.18%; that's higher than 94.76% of US stocks.
- If you're looking for stocks that are quantitatively similar to Xtant Medical Holdings Inc, a group of peers worth examining would be SMTI, HURC, GROW, APAM, and NBY.
- Visit XTNT's SEC page to see the company's official filings. To visit the company's web site, go to www.xtantmedical.com.
XTNT Valuation Summary
- XTNT's price/earnings ratio is -38.6; this is 205.75% lower than that of the median Healthcare stock.
- XTNT's price/earnings ratio has moved down 2013.6 over the prior 136 months.
- XTNT's price/sales ratio has moved down 51.4 over the prior 136 months.
Below are key valuation metrics over time for XTNT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| XTNT | 2021-08-31 | 2 | 3.2 | -38.6 | 210.7 |
| XTNT | 2021-08-30 | 2 | 3.2 | -38.3 | 208.9 |
| XTNT | 2021-08-27 | 2 | 3.4 | -40.2 | 219.2 |
| XTNT | 2021-08-26 | 2 | 3.3 | -39.3 | 214.1 |
| XTNT | 2021-08-25 | 2 | 3.2 | -38.3 | 208.9 |
| XTNT | 2021-08-24 | 2 | 3.2 | -38.3 | 208.9 |
XTNT Growth Metrics
- Its 2 year price growth rate is now at -89.61%.
- The 2 year net cashflow from operations growth rate now stands at -262.13%.
- The 3 year cash and equivalents growth rate now stands at 52.02%.
The table below shows XTNT's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 55.263 | 0.439 | -4.849 |
| 2021-09-30 | 55.309 | 0.932 | -3.272 |
| 2021-06-30 | 55.548 | 1.787 | -2.828 |
| 2021-03-31 | 51.102 | -0.249 | -4.559 |
| 2020-12-31 | 53.337 | -0.731 | -7.023 |
| 2020-09-30 | 56.287 | -1.718 | -7.922 |
XTNT Stock Price Chart Interactive Chart >
XTNT Price/Volume Stats
| Current price | $0.48 | 52-week high | $2.38 |
| Prev. close | $0.52 | 52-week low | $0.45 |
| Day low | $0.45 | Volume | 40,900 |
| Day high | $0.51 | Avg. volume | 44,846 |
| 50-day MA | $0.57 | Dividend yield | N/A |
| 200-day MA | $0.75 | Market Cap | 41.91M |
Xtant Medical Holdings, Inc. (XTNT) Company Bio
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and devices in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as could be used in conjunction with a hardware plate system. The company is based in Montana.
Latest XTNT News From Around the Web
Below are the latest news stories about Xtant Medical Holdings Inc that investors may wish to consider to help them evaluate XTNT as an investment opportunity.
Xtant Medical to Present at the H.C. Wainwright BioConnect Virtual ConferenceBELGRADE, Mont., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, Chief Executive Officer, will present at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022. A pre-recorded presentation will be available on the Investors section of the Company’s website at www.xtantmedical.com, beginning on |
Xtant Medical Appoints Scott Neils Interim Chief Financial OfficerBELGRADE, Mont., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Scott Neils as Interim Chief Financial Officer succeeding Greg Jensen, the Company’s current Vice President, Finance and Chief Financial Officer, effective January 3, 2022. “We are excited to announce this well deserved promotion for Scott. His demonstrated |
Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest UpdateXtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the target of a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 197,600 shares, a decrease of 21.7% from the October 31st total of 252,500 shares. Based on an average daily volume of 140,900 shares, the days-to-cover ratio [] |
Xtant Medical Holdings'' (XTNT) CEO Sean Browne on Q3 2021 Results - Earnings Call TranscriptNo summary available. |
Xtant Medical Announces Third Quarter 2021 Financial ResultsBELGRADE, Mont., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2021. |
XTNT Price Returns
| 1-mo | -26.13% |
| 3-mo | -31.43% |
| 6-mo | -25.00% |
| 1-year | -71.08% |
| 3-year | -81.68% |
| 5-year | -93.55% |
| YTD | -14.29% |
| 2021 | -53.18% |
| 2020 | -25.24% |
| 2019 | -0.62% |
| 2018 | -76.46% |
| 2017 | 3.64% |
Continue Researching XTNT
Want to see what other sources are saying about Xtant Medical Holdings Inc's financials and stock price? Try the links below:Xtant Medical Holdings Inc (XTNT) Stock Price | Nasdaq
Xtant Medical Holdings Inc (XTNT) Stock Quote, History and News - Yahoo Finance
Xtant Medical Holdings Inc (XTNT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...